IL1B and intervertebral disk degenerative disorder: While acknowledging the complicated nature of DDD, and the potential for different drivers of inflammation, there is already promising experimental evidence of the ability of IL-1β-targeted approaches to affect pathogenic mechanisms of the condition both in vitro and in vivo, promoting ECM repair and inhibiting disc degeneration (Gorth et al., 2012).